Werewolf Therapeutics Inc. (HOWL) Financial Statements (2025 and earlier)

Company Profile

Business Address 200 TALCOTT AVENUE
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments135,303139,189134,343130,058137,452147,868
Cash and cash equivalents135,303139,189134,343130,058137,452147,868
Restricted cash and investments  212211210 207
Receivables5457751,3506,8116,9278,055
Other undisclosed current assets2,9402,1082,4662,1793,020432
Total current assets:138,788142,284138,370139,258147,399156,562
Noncurrent Assets
Operating lease, right-of-use asset6,3476,5126,8887,2517,7888,127
Property, plant and equipment7,0927,5297,9588,3428,3818,699
Restricted cash and investments1,21121,02721,02321,01921,01521,011
Other noncurrent assets265248594516652670
Total noncurrent assets:14,91535,31636,46337,12837,83638,507
TOTAL ASSETS:153,703177,600174,833176,386185,235195,069
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,1687,80910,1969,35311,43015,427
Accounts payable1,4671,5941,3361,3861,4902,106
Accrued liabilities8,7016,2158,8607,9679,94013,321
Deferred revenue  5029071,814  
Debt  11,6676,6671,667  
Other liabilities     1,6064,149
Other undisclosed current liabilities1,2741,2361,6081,6051,9702,146
Total current liabilities:11,44221,21419,37814,43915,00621,722
Noncurrent Liabilities
Long-term debt and lease obligation25,16327,74832,65637,56439,14239,063
Long-term debt, excluding current maturities25,16327,74832,65637,56439,14239,063
Liabilities, other than long-term debt10,23911,05111,42511,94012,48813,211
Deferred revenue  4314335887831,168
Operating lease, liability10,23910,62010,99211,35211,70512,043
Other undisclosed noncurrent liabilities2,841     
Total noncurrent liabilities:38,24338,79944,08149,50451,63052,274
Total liabilities:49,68560,01363,45963,94366,63673,996
Equity
Equity, attributable to parent104,018117,587111,374112,443118,599121,073
Common stock444333
Additional paid in capital481,529477,849455,443444,510442,381439,757
Accumulated deficit(377,515)(360,266)(344,073)(332,070)(323,785)(318,687)
Total equity:104,018117,587111,374112,443118,599121,073
TOTAL LIABILITIES AND EQUITY:153,703177,600174,833176,386185,235195,069

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues   1,562  400
Sublease income      400
Gross profit:      400
Operating expenses(20,103)(17,904)(14,463)(15,148)(14,148)(16,687)
Other undisclosed operating income 1,1437421,5015,8978,0814,064
Operating loss:(18,960)(17,162)(12,962)(9,251)(6,067)(12,223)
Nonoperating income1,711969959966969241
Investment income, nonoperating1,7931,973 9719941,347
Other nonoperating income (expense)1,613(1) (5)(25)(1,106)
Interest and debt expense(553)(1,003)    
Other undisclosed loss from continuing operations before equity method investments, income taxes   (3,139)   
Net loss:(17,802)(17,196)(15,142)(8,285)(5,098)(11,982)
Other undisclosed net income attributable to parent5531,0033,139   
Net loss available to common stockholders, basic:(17,249)(16,193)(12,003)(8,285)(5,098)(11,982)
Interest on convertible debt 120     
Other undisclosed net loss available to common stockholders, diluted (1,609)     
Net loss available to common stockholders, diluted:(18,738)(16,193)(12,003)(8,285)(5,098)(11,982)

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net loss:(17,802)(17,196)(15,142)(8,285)(5,098)(11,982)
Comprehensive loss, net of tax, attributable to parent:(17,802)(17,196)(15,142)(8,285)(5,098)(11,982)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: